Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB. RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849956 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2019000526 | DOI Listing |
Publication Analysis
Top Keywords
five-year outcomes
4
outcomes s1106
4
s1106 study
4
study r-hyper-cvad
4
r-hyper-cvad r-bendamustine
4
r-bendamustine transplant-eligible
4
transplant-eligible patients
4
patients mantle
4
mantle cell
4
cell lymphoma
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!